



US 20070098778A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2007/0098778 A1**
Borsadia (43) **Pub. Date: May 3, 2007**

(54) **CO-FORMULATIONS OR KITS OF BIOACTIVE AGENTS**

(52) **U.S. Cl.** **424/451; 514/369; 514/423; 514/460; 514/548; 514/635**

(75) **Inventor: Suresh Borsadia, Plainsboro, NJ (US)**

(57) **ABSTRACT**

Correspondence Address:
ROGER GLENN HENDRICKS
3203 YOST
PEARLAND, TX 77581 (US)

Provided, among other things, is a formulation or kit comprising:

(73) **Assignee: ABEILLE PHARMACEUTICALS, INC., Princeton, NJ (US)**

(a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α -glucosidase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPAR α/γ agonist, PPAR γ agonist or insulin secretagogue; and

(21) **Appl. No.: 10/595,884**

(b) a pharmaceutically effective dosage of (i) one or more of an antihypertensive bioactive agent selected from an ACE inhibitor, calcium channel blocker, beta blocker, angiotension II receptor antagonist or diuretic, or (ii) one or more of an anti-dyslipidemia bioactive agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative;

(22) **PCT Filed: Feb. 28, 2005**

(86) **PCT No.: PCT/US05/06043**

§ 371(c)(1),
(2), (4) **Date: May 18, 2006**

wherein:

Related U.S. Application Data

(60) **Provisional application No. 60/549,420, filed on Mar. 2, 2004.**

in the case of (i) a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group (a) that is a thiazolidinedione or dual PPAR α/γ agonist with an angiotension II receptor antagonist, one or more of the following applies:

Publication Classification

(51) **Int. Cl.**
A61K 31/426 (2006.01)
A61K 31/401 (2006.01)
A61K 31/366 (2006.01)
A61K 31/22 (2006.01)
A61K 31/155 (2006.01)
A61K 9/48 (2006.01)

(1) one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or

(11) the co-formulation or kit comprises (A) a biguanide and a thiazolidinedione and (B) one or more group (b) bioactive agents.




Fig. 1

Fig. 2




Fig. 3




Fig. 4

CO-FORMULATIONS OR KITS OF BIOACTIVE AGENTS

[0001] The present invention relates to the use of multi-bioactive agent administration products having two or more different bioactive agents indicated for two or more different disease conditions to an individual in need of such bioactive agents. More specifically, the invention relates to co-formulations or kits of two or more different bioactive agents for treating diabetes and its co-morbidities (including co-existing disease conditions), including hypertension, dyslipidemia, cardiovascular disease, and nephropathy

[0002] According to studies cited in Merck Manual, only about half of patients who leave a physician's office with a prescription take the medication as directed. The most common reason given for noncompliance is forgetfulness. Other reasons for noncompliance with medication regimens include lack of understanding or confusion about dosing. Older persons with cognitive impairment often find the dosing regimen complex, and difficult to remember and to follow.

[0003] Current therapeutic regimens for individuals having two or more separate disease conditions typically involve treatment with two or more different and distinct bioactive agents, which often need to be given at separate times. The individuals need to take each bioactive agent at its required time for maximum therapeutic effect. Individuals who must take multiple bioactive agents on multiple schedules to treat more than one disease condition often find this multi-bioactive agent administration regimen very confusing and even more difficult to follow. Multi-bioactive agent administration is especially difficult for elderly patients who often have several co-existing conditions needing therapeutic treatment.

[0004] Various solutions have been suggested for improving patient compliance with medication dosing, including intervention by the physician and/or pharmacist. However, it is generally accepted that the best possible dosing regimen for patient compliance is a simplified regimen, especially a once-daily dosing regimen.

[0005] There is recent evidence based on prospective and retrospective analysis that comorbidity of hyperlipidemia and diabetes is prevalent and could benefit from concomitant treatment with an anti-dyslipidemia agent and a glucose controlling agent.

[0006] Co-administration of these bioactive agents however is often difficult since the glucose lowering agent often needs to be dosed multiple times a day and the anti-dyslipidemia agent is typically administered once a day, preferably at night time. A single administration of anti-diabetic bioactive agent can be achieved by formulating the bioactive agent in a sustained release dosage form. However, addition of the anti-dyslipidemia agent in the same sustained release dosage form could inappropriately control the second bioactive agent's release such that it would be difficult to achieve therapeutic levels.

[0007] U.S. Pat. No. 6,660,300 to Timmins et al describes a delivery system wherein Metformin and optionally a hypolipidemic agent are administered in a biphasic system. The delivery system's two phases are: an inner solid particulate phase of granules containing a highly water soluble

and an outer solid continuous phase in which the inner solid particulate phase granules are dispersed. The outer solid continuous phase is formed of an extended release material with hydrophobic polymers or materials. Since both phases in the described system contain hydrophobic polymers, it is likely to control the release of not only highly soluble Metformin which requires an extended release profile, but will also inhibit the release of any hypolipidemic agent, leading to sub-therapeutic levels of the hypolipidemic agent.

[0008] WO 2004/017896 A2, to Waldstreicher et al, describes a combination bioactive agent therapy for the treatment of hypertension and type 2 diabetes mellitus, Metabolic Syndrome, or a pre-diabetic condition in a patient in need of such treatment. The invention describes the use of combinations of pharmaceutically active compounds that are dual agonists of the alpha and gamma subtypes of the peroxisome proliferators activated receptor (PPAR α/γ) with Angiotensin II Type I receptor (A-2) antagonists. The invention does not specifically address the combinations of other bioactive agents for treatment of diabetes and comorbidities, particularly where the bioactive agents have distinct treatment regimens.

[0009] What is needed then is a multi-bioactive agent administration product for concurrently treating two distinct disease conditions each of which has distinct treatment options and different treatment regimens.

[0010] SUMMARY OF THE INVENTION

[0011] Provided, among other things, is a formulation or kit comprising:

[0012] (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α -glucosidase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPAR α/γ agonist, PPAR γ agonist or insulin secretagogue; and

[0013] (b) a pharmaceutically effective dosage of (i) one or more of an antihypertensive bioactive agent selected from an ACE inhibitor, calcium channel blocker, beta blocker, angiotensin II receptor antagonist or diuretic, or (ii) one or more of an anti-dyslipidemia bioactive agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative;

wherein:

[0014] in the case of (i) a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group (a) that is a thiazolidinedione or dual PPAR α/γ agonist with an angiotensin II receptor antagonist, one or more of the following applies:

[0015] (I) one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or

[0016] (II) the co-formulation or kit comprises (A) a biguanide and a thiazolidinedione and (B) one or more group (b) bioactive agents.

[0017] The multi-bioactive agent administration product

[0018] In certain embodiments, such a co-formulation is a capsule wherein

[0019] one or more group (a) bioactive agents are formulated in sustained release beads comprised within the capsule; and

[0020] one or more group (b) bioactive agents in a more immediate release form are comprised within the capsule.

[0021] In certain embodiments, such a co-formulation is a compression formulation wherein

[0022] one or more group (a) bioactive agents are formulated in sustained release form comprised within a portion of the compression formulation; and

[0023] one or more group (b) bioactive agents in a more immediate release form are comprised within another portion of the compression formulation.

[0024] In certain embodiments, such a co-formulation is a suspension formulation wherein

[0025] one or more group (a) bioactive agents are formulated in sustained release form comprised within particles that are suspended or adapted to be suspended in a liquid; and

[0026] one or more group (b) bioactive agents are dissolved in the liquid.

The instructions for the co-formulation may provide that it should be shaken immediately prior to use (to suspend particles). Particles may be beads, such as described below. Bead and liquid density can be selected to increase bead propensity to remain in suspension.

[0027] In certain embodiments the invention provides, among other things, methods of treating diabetes or its co-morbidities. One such method is for delivering in the co-formulation a glucose-level-controlling bioactive agent and a second bioactive agent for treating a co-morbidity of diabetes, the glucose-level-controlling bioactive agent having a first dosing regimen and the second bioactive agent having a second, distinct dosing regimen, wherein the co-formulation provides a pharmacokinetic profile of the glucose-level-controlling bioactive agent that mimics the first dosing regimen and a pharmacokinetic profile of the second bioactive agent that mimics the second dosing regimen.

BRIEF DESCRIPTION OF THE DRAWINGS

[0028] FIG. 1 is an embodiment of a kit of the invention.

[0029] FIG. 2 is another embodiment of a kit of the invention.

[0030] FIG. 3 is a further embodiment of a kit of the invention.

[0031] FIG. 4 shows dissolution profiles of formulations of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Dual Release Embodiments

[0032] In certain embodiments, the invention provides

second bioactive agent for treating a co-morbidity of diabetes, the glucose-level-controlling bioactive agent having a first dosing regimen and the second bioactive agent having a second, distinct dosing regimen, wherein the co-formulation provides a pharmacokinetic profile of the glucose-level-controlling bioactive agent that mimics the first dosing regimen and a pharmacokinetic profile of the second bioactive agent that mimics the second dosing regimen.

[0033] The present invention provides, in one embodiment, a novel method of concurrently treating diabetes and co-morbidities, such as hypertension or dyslipidemia, by utilizing a multi-bioactive agent administration product to deliver a glucose level controlling bioactive agent, such as one which requires a controlled release dosage form, and a second bioactive agent, such as one which requires an immediate release dosage form, such as an anti-dyslipidemia bioactive agent or an anti-hypertension bioactive agent, in a single product. The multi-bioactive agent administration product of the present invention may comprise a co-formulation or a kit. An exemplary co-formulation is provided wherein a glucose-level-controlling bioactive agent is formulated as a controlled release product and another bioactive agent is delivered in an immediate release formulation in the same overall dosage form. The multi-bioactive agent administration product of the invention may also comprise a kit, wherein each individual bioactive agent may be formulated in a separate dosage form but their presentation together in a single kit enhances patient compliance and improves the ease of bioactive agent administration over taking each bioactive agent separately from a separate bottle.

[0034] The present invention also provides, in one embodiment, a co-formulation of a first highly water soluble bioactive agent in a controlled release dosage form using a blend of hydrophobic and hydrophilic polymers to provide controlled release of the bioactive agent where needed, with a second immediate release bioactive agent, and a method of formulating such co-formulation.

[0035] While coating techniques using a core-coat combination are known in the formulation of pharmaceutical agents, these techniques have typically been applied to control the release of either a single active ingredient or as a method to prevent interaction between two bioactive agents. Thus, the invention provides an ability to deliver two such bioactive agents in a single daily dosage form or single dosage combination (in a kit), one with an otherwise typical once a day dosing regimen and another with an otherwise typical more frequent dosing during the day. This invention also provides formulating techniques to provide a single dosage form wherein the pharmacokinetic profiles of each of the included bioactive agents will mimic their respective single dose or multidose equivalents. In this way, multiple bioactive agents may be administered in a single dosage form, even when each bioactive agent has its own specific and distinct dosing regimen different from the other bioactive agent(s) in the single dosage form.

[0036] In one aspect the invention provides a co-formulation of an glucose level controlling bioactive agent with an anti-dyslipidemia bioactive agent or with another bioactive agent directed against a co-morbidity of diabetes. A glucose level controlling bioactive agent, such as for example Met-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.